Receptor Density Affects Circadian Rhythms in the Biological Clock

Release time:

2024-07-26

Researchers at Washington University in St. Louis are delving into the mechanisms of the human biological clock and how it keeps time. Their latest findings, published on July 24 in the Proceedings of the National Academy of Sciences, shed light on longstanding questions about the generation and maintenance of circadian rhythms.


In animals, signals from a central brain clock generate seasonal and daily rhythms. These signals help the body prepare for expected environmental changes, optimizing sleep, diet, and daily activities. In mammals, circadian signals originate from a small region in the brain called the suprachiasmatic nucleus (SCN). Previous studies by Washington University and other institutions have tried to determine if the neurotransmitter GABA plays a role in synchronizing circadian rhythms among individual SCN neurons. However, GABA's function in the SCN remains unclear.
"In the past, we've published data on blocking the GABA system and found only modest increases in synchrony among SCN cells," said Daniel Granados-Fuentes, the first author of the new study. Consequently, Granados-Fuentes and his team adopted a different approach. The researchers modified the expression of two GABA receptors to assess whether receptor density impacts synchrony or behavior.


Granados-Fuentes explained, "Regulating the number of receptors is considered important for physiological processes like learning and memory, but not for circadian rhythms." However, in this case, altering the density of γ-2 or δ GABA receptors had significant effects. Reducing these receptors in mutant mice lowered the amplitude of their circadian rhythms to one-third. The mice also increased their daytime running and decreased nighttime running.


The researchers found that reducing or mutating γ-2 or δ GABA receptors halved the synchrony and amplitude of circadian SCN cells' measurements in vitro. Overexpression of either GABA receptor could compensate for the absence of the other, suggesting that both receptors might function similarly in the SCN despite mediating different physiological processes.
These findings advance our understanding of the SCN and highlight the crucial role of GABA receptor density in regulating circadian rhythms. This research provides a foundation for future studies that could explore therapeutic strategies for circadian rhythm disorders.

Latest News

FDA Approves First Nasal Spray for Emergency Allergic Reactions

On August 9, 2024, the U.S. Food and Drug Administration (FDA) approved Neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals, for the emergency treatment of type I allergic reactions in adults and children weighing at least 30 kg. This marks the first non-injection epinephrine product approved by the FDA.

2024/08/23

First Non-Addictive Painkiller Application Submitted in 20 Years

On August 20, 2024, Scientific American reported that Vertex Pharmaceuticals (VRTX.US) has developed a novel painkiller capable of reducing acute pain levels by approximately 50% without the risk of addiction. On July 30, 2024, Vertex announced that the U.S. Food and Drug Administration (FDA) had accepted a New Drug marketing application for the drug and granted priority review status. The drug, VX-548, is used to treat moderate to severe acute pain. If approved, VX-548 will be the first non-opioid acute pain medication to hit the market in two decades, marking a significant milestone in pain management.

2024/08/22

AAV Gene Therapy: A Potential Breakthrough for Rare Disease Treatment

Seven-year-old Canadian child Michael Piravola was diagnosed with a mutation in his AP4M1 gene at just 18 months old. By the age of two, he was diagnosed with hereditary spastic paraplegia type 50, an ultra-rare condition characterized by developmental delays, microcephaly, speech impairments, and limitations in standing and walking.

2024/08/12